汕头大学医学院学报2024，Vol.37Issue(4)：193-199,7.DOI:10.13401/j.cnki.jsumc.2024.04.001
基于网络药理学探讨慈丹胶囊治疗原发性肝癌的主要药效成分及靶点
Investigation of the main pharmacodynamic components and targets of Cidan Capsule against primary liver cancer based on network pharmacology
摘要
Abstract
Objective:To investigate the key components and targets of action of Cidan Capsule in the treatment of primary liver cancer.Methods:With the help of network pharmacology-related databases and analysis platforms(HERB,OMIM,Cytoscape,etc.),the potential targets of Cidan Capsule in the treatment of primary liver cancer were predicted,a protein-protein interaction network was constructed,GO and KEGG enrichment analysis was performed,and molecular docking was performed using Autodock software to predict key components and targets.The prediction results were further verified by experiments such as cell proliferation,cell scratch,and RT-qPCR.Results:Through network pharmacology analysis,32 common targets of Cidan Capsule-primary liver cancer were screened,and the main core components of Cidan Capsule were apigenin,sophorine,quercetin,and kaempferol.The molecular docking results showed that the key component of Cidan Capsule with therapeutic effect on primary liver cancer was apigenin,and the target was CTNNB1,and the binding energy of the two was-1.537 kcal/mol.The inhibitory effect of apigenin on the proliferation and migration of HepG2 cells was verified by CCK-8 cell proliferation and cell scratch experiments,and the inhibitory effect of apigenin on CTNNB1 gene expression in HepG2 cells was verified by RT-qPCR experiment.Conclusion:Apigenin may be the key component of Cidan Capsule in the treatment of primary liver cancer,and the target is CTNNB1;Apigenin can inhibit the proliferation,migration and CTNNB1gene expression of HepG2 cells.关键词
慈丹胶囊/原发性肝癌/网络药理学/芹菜素/CTNNB1Key words
Cidan Capsule/primary liver cancer/network pharmacology/apigenin/CTNNB1分类
医药卫生引用本文复制引用
辜竹萌,陈怡妹,林贵祥,黄欣愉,贾佳,鄢占魁,高分飞..基于网络药理学探讨慈丹胶囊治疗原发性肝癌的主要药效成分及靶点[J].汕头大学医学院学报,2024,37(4):193-199,7.基金项目
广东省中医药局科研项目(20231197) （20231197）
广东省科技创新战略专项(大专项+任务清单)项目(STKJ2023050) （大专项+任务清单）
广东省药学会临床用药研究基金(2023JZ17) （2023JZ17）
